论文部分内容阅读
目的:观察宣痹汤联合甲氨蝶呤、来氟米特治疗类风湿性关节炎的临床疗效。方法:将70例类风湿性关节炎患者按随机数字表法分为治疗组和对照组各35例,对照组患者采用甲氨蝶呤、来氟米特治疗,治疗组患者加用宣痹汤加减口服,观察比较两组患者治疗前后ESR(红细胞沉降率)、CRP(C-反应蛋白)的含量及临床疗效。结果:两组患者临床症状及实验室指标等均较治疗前明显改善(P<0.05);经治疗,治疗组患者治疗总有效率为80.0%,高于对照组的74.3%,差异具有统计学意义(P<0.05)。结论:宣痹汤联合甲氨蝶呤、来氟米特可明显改善类风湿性关节炎患者临床症状,降低实验室指标,且安全性好,值得临床推广应用。
Objective: To observe the clinical efficacy of Xuanbi Decoction combined with methotrexate and leflunomide in the treatment of rheumatoid arthritis. Methods: Seventy patients with rheumatoid arthritis were randomly divided into treatment group and control group according to random number table, 35 cases in each group. Patients in the control group were treated with methotrexate and leflunomide. Patients in the treatment group were treated with Xuanbi Tonga Oral reduction, observed and compared ESR (erythrocyte sedimentation rate), CRP (C-reactive protein) content and clinical efficacy of two groups before and after treatment. Results: The clinical symptoms and laboratory indexes in both groups were significantly improved compared with those before treatment (P <0.05). After treatment, the total effective rate of the treatment group was 80.0%, higher than that of the control group (74.3%), the difference was statistically significant Significance (P <0.05). Conclusion: Xuanbi Decoction combined methotrexate and leflunomide can significantly improve the clinical symptoms of patients with rheumatoid arthritis, reduce laboratory indicators, and the safety is good, worthy of clinical promotion and application.